Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.54 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | PGR | P06401 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | AR | P10275 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9403377 | 0.86 | PGR (0.50) | ACHEESR1SMN1; SMN2OPRM1PGR | |
| SCHEMBL9403350 | 0.78 | OPRM1 (0.56) | ACHEESR1SMN1; SMN2OPRM1PGR | |
| Acetic Acid SCHEMBL20533151 | 0.77 | ESR1 (0.50) | ACHEESR1OPRD1 | |
| Acetic Acid SCHEMBL20533149 | 0.77 | ESR1 (0.50) | ACHEESR1OPRD1 | |
| SCHEMBL9261533 | 0.77 | ALOX15 (0.56) | ESR1SMN1; SMN2PGRADORA3AR | |
| SCHEMBL267052 | 0.76 | DRD2 (0.51) | ACHE | |
| SCHEMBL1565115 | 0.76 | DRD2 (0.51) | ACHE | |
| SCHEMBL3295841 | 0.75 | ACHE (0.61) | ACHE | |
| Hydrochloric Acid SCHEMBL10357354 | 0.75 | DRD2 (0.50) | — | |
| SCHEMBL14272024 | 0.74 | ACHE (0.47) | ACHEESR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3609886-B1 | BENZOAZEPINE ANALOGS AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-11858926-B2 | Inhibiting agents for bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4249071-A2 | BENZOAZEPINE ANALOGS AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230147490-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2023-05-11 | — | — | US | disclosed |
| US-11427577-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20210340135-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2021-11-04 | — | — | US | disclosed |
| US-10961237-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200239459-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2020-07-30 | — | — | US | disclosed |
| EP-3609886-A1 | BENZOAZEPINE ANALOGS AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| US-10227341-B2 | Inhibiting agents for bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10189829-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180362522-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2018-12-20 | — | — | US | disclosed |
| US-20180297992-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2018-10-18 | — | — | US | disclosed |
| WO-2018191577-A1 | BENZOAZEPINE ANALOGS AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227341-B2 | Inhibiting agents for bruton's tyrosine kinase | ABL1, BTK, LYN | ACHE 4632/4885ESR1 4163/4885SMN1; SMN2 1634/4885 |
| US-10961237-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | ACHE 4632/4885ESR1 4163/4885SMN1; SMN2 1634/4885 |
| US-20210340135-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | ACHE 4632/4885ESR1 4163/4885SMN1; SMN2 1634/4885 |
| US-20180362522-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | ACHE 4632/4885ESR1 4163/4885SMN1; SMN2 1634/4885 |
| US-20200239459-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | ACHE 4632/4885ESR1 4163/4885SMN1; SMN2 1634/4885 |
| US-11427577-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | ACHE 4632/4885ESR1 4163/4885SMN1; SMN2 1634/4885 |
| US-20180297992-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | ACHE 4632/4885ESR1 4163/4885SMN1; SMN2 1634/4885 |
| US-10189829-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | ACHE 4632/4885ESR1 4163/4885SMN1; SMN2 1634/4885 |
| US-11858926-B2 | Inhibiting agents for bruton's tyrosine kinase | ABL1, BTK, LYN | ACHE 4632/4885ESR1 4163/4885SMN1; SMN2 1634/4885 |
| US-20230147490-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | ACHE 4632/4885ESR1 4163/4885SMN1; SMN2 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.